CivicaScript will initially develop and manufacture 6 to 10 medicines for which there currently is not enough market competition to drive down prices.

As our membership grows and funding increases, the number of medicines we produce will grow.

CivicaScript’s sister company, Civica, Inc. (Civica Rx) is building a manufacturing plant to produce affordable insulin for our hospital members and retail consumers. This lower-cost insulin will be available once we begin manufacturing it in 2024. The availability of affordable insulins will benefit people with diabetes who have been forced to choose between life-sustaining medicines and living expenses, particularly those uninsured or underinsured who often pay the most out of pocket for their medications.


Our first medicine is expected to be available in the U.S. this summer.